Starling Oncology (STLNW) Other Working Capital Changes (2021)

Starling Oncology (STLNW) has reported Other Working Capital Changes for 1 consecutive years, with $3.0 million the latest figure, recorded in Q3 2021.

• For the quarter ending Q2 2026, Other Working Capital Changes fell 828.57% year-over-year to -$306000.0; the trailing twelve-month figure through Jun 2026 stood at -$824000.0 (down 1598.18% YoY), and the FY2025 full-year result was -$452000.0, down 180.86% from the prior year.
• Other Working Capital Changes slipped to -$306000.0 in Q2 2026 per STLNW's latest filing, from -$186000.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $5.7 million in Q2 2021 and bottomed at $353000.0 in Q1 2021.
• Historically, Other Working Capital Changes has averaged -$528333.3 across 5 years, with a median of -$554500.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Other Working Capital Changes slumped 2867.74% in 2022, then jumped 238.65% in 2024.
• Over 5 years, Other Working Capital Changes stood at -$803000.0 in 2022, then plunged by 76.21% to -$1.4 million in 2023, then soared by 93.57% to -$91000.0 in 2024, then plunged by 95.6% to -$178000.0 in 2025, then plunged by 71.91% to -$306000.0 in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$306000.0, -$186000.0, and -$178000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.